Page 196 - Read Online

Glinsky Genetic signatures of lethal disease in early stage prostate cancer

prostate cancer at the time when no PSA screening the specific needs, which will be ultimately tailored to
programs were in place: these men had symptoms the need of the particular individual patient.
of benign prostatic hyperplasia (lower urinary tract
symptoms) and were subsequently diagnosed with DECLARATIONS
prostate cancer. No PSA analyses were performed and
these patients did not receive treatment for prostate Acknowledgments
cancer. Therefore, the prostate cancer-specific This work was made possible by the open public
death reported in this study represent the realistic access policies of major grant funding agencies and
natural history of prostate cancer with respect to the international genomic databases and the willingness
assessment of what happen to the prostate cancer of many investigators worldwide to share their primary
patients if they will not be treated and just subjected research data. I would like to thank many colleagues
to observations. In this contribution we evaluated the for their valuable critical contributions during the
prostate cancer-specific death as the main outcome. preparation of this manuscript.

It has been reported that changes in prostate cancer Authors’ contributions
screening practices in the United States have been G.V. Glinsky contributed solely to the paper.
associated with the recent decline in the overall
incidence of prostate cancer and concomitant Financial support and sponsorship
significant increase of the annual incidence of None.
metastatic prostate cancer from 2007 to 2013.
[23]
Statistically significant increase in the annual incidence Conflicts of interest
of metastatic prostate cancer in the United States from There are no conflicts of interest.
2007 to 2013 has been consistently documented in
all age groups with the overall increase of 72% in Patient consent
2013 compared to 2004. Particularly alarming is the Not applicable.
evidence of the greatest increase of the incidence of Ethics approval
metastatic prostate cancer in men of the age group
of 55 to 69 years who experienced 92% increase Not applicable.
in the incidence of metastatic disease from 2004
to 2013. These patients are likely to benefit most REFERENCES
[23]
from definitive curative treatment of prostate cancer, 1. American Cancer Society: American Cancer Society Cancer Facts and
suggesting that relaxed screening protocols and Figures 2010. Atlanta, GA: American Cancer Society; 2010.
transition to active surveillance with curative intent 2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer
strategy as a predominant approach for treatment statistics, 2008. CA Cancer J Clin 2008;58:71-96.
of early-stage prostate cancer should be considered 3. Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L,
with extreme caution for this group of men, particularly Magnuson A, Adami HO. Natural history of early, localized prostate
in the absence of validated genetic tests reliably cancer. JAMA 2004;291:2713-9.
discriminating indolent prostate cancers from the 4. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward
E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B, Edwards
clinically significant disease. BK. Annual report to the nation on the status of cancer, 1975-2005,
featuring trends in lung cancer, tobacco use, and tobacco control. J
It is outside of the scope of this contribution to Natl Cancer Inst 2008;100:1672-94.
compare the diagnostic, prognostic, therapy- 5. Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO,
outcome assessments or targeted therapy-selection Bratell S, Spångberg A, Busch C, Nordling S, Garmo H, Palmgren J,
performances of GES. These questions were Adami HO, Norlén BJ, Johansson JE; Scandinavian Prostate Cancer
extensively explored and debated in the literature. Group Study No. 4. Radical prostatectomy versus watchful waiting in
early prostate cancer. N Engl J Med 2005;352:1977-84.
There is no need to attempt a “horse race” comparing 6. Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C,
the signatures against each other while the state of Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A,
the art comprehensive microarray and/or RNA-seq Palmgren J, Adami HO, Johansson JE; Scandinavian Prostate Cancer
platforms enable the analyses of all of the signatures in Group Study Number 4. Radical prostatectomy versus watchful
one run and score all of the signatures simultaneously waiting in localized prostate cancer: the Scandinavian prostate cancer
can be made for the specifically-defined benefits of group-4 randomized trial. J Natl Cancer Inst 2008;100:1144-54.
the patients. It is reasonable to expect that no single 7. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch
C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg
signature will fit all clinically-defined disease diagnosis A, Palmgren J, Steineck G, Adami HO, Johansson JE; SPCG-4
and management criteria and different signatures will Investigators. Radical prostatectomy versus watchful waiting in early
address more adequately and resolve more efficiently prostate cancer. N Engl J Med 2011;364:1708-17.
188 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ September 21, 2017